FDA Approval Insights: Durvalumab Plus Tremelimumab in HCC

Nov 24, 2022

In Partnership With:

Dr Abou-Alfa discusses the FDA approval of durvalumab plus tremelimumab in unresectable hepatocellular carcinoma, the regimen’s unique mechanism of action, and the importance of expanding global access to this combination.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Ghassan K. Abou-Alfa, MD, an attending physician at Memorial Sloan Kettering Cancer Center in New York, New York. Dr Abou-Alfa joined us to speak about the FDA approval of durvalumab (Imfinzi) plus tremelimumab (Imjudo) in hepatocellular carcinoma (HCC).

On October 24, 2022, the FDA approved the combination of durvalumab and tremelimumab for adult patients with unresectable HCC. The regulatory decision was supported by the results of the phase 3 HIMALAYA trial (NCT03298451), in which the Single Tremelimumab Regular Interval Durvalumab (STRIDE) regimen elicited an overall survival (OS) of 16.43 months vs 13.77 months with sorafenib (Nexavar). The 3-year OS rates were 30.7% with the combination vs 20.2% with sorafenib.

In our exclusive interview, Dr Abou-Alfa discussed the significance of this approval, the STRIDE regimen’s unique mechanism of action, and the importance of expanding access to this combination for patients around the world.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
View All
Related Content